TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Key Inclusion Criteria:~* Part 1: Heterozygous for F508del and an MF mutation (F/MF)~* Part 2: Homozygous for F508del (F/F)~* FEV1 value ≥40% and ≤90% of the predicted mean for age, sex, and height~Key Exclusion Criteria:~* History of clinically significant cirrhosis with or without portal hypertension~* Lung infection with organisms associated with a more rapid decline in pulmonary status~* History of solid organ or hematological transplantation~Other protocol-defined Inclusion/Exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part 1: Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo matched to VX-121/TEZ/VX-561 triple combination (TC) for 4 weeks in the treatment period and placebo matched to TEZ/VX-561 for 18 days in the washout period.
- Part 1: VX-121/TEZ/VX-561 TC - Low Dose (Type: EXPERIMENTAL): Participants received VX-121 5 milligram (mg) once daily (qd)/TEZ 100 mg qd/VX-561 150 mg qd TC for 4 weeks in the treatment period and TEZ 100 mg qd/VX-561 150 mg qd for 18 days in the washout period
- Part 1: VX-121/TEZ/VX-561 TC - Medium Dose (Type: EXPERIMENTAL): Participants received VX-121 10 mg qd/TEZ 100 mg qd/VX-561 150 mg qd TC for 4 weeks in the treatment period and TEZ 100 mg qd/VX-561 150 mg qd for 18 days in the washout period.
- Part 1: VX-121/TEZ/VX-561 TC - High Dose (Type: EXPERIMENTAL): Participants received VX-121 20 mg qd/TEZ 100 mg qd/VX-561 150 mg qd TC for 4 weeks in the treatment period and TEZ 100 mg qd/VX-561 150 mg qd for 18 days in the washout period.
- Part 2: TEZ/IVA (Type: ACTIVE_COMPARATOR): Following run-in period with TEZ 100 mg qd/IVA 150 mg every 12 hours (q12h) for 4 weeks, participants received TEZ 100 mg qd/IVA 150 mg q12h for 4 weeks in the treatment period and TEZ 100 mg/IVA 150 mg q12h for 4 weeks in the washout period.
- Part 2: VX-121/TEZ/VX-561 TC - High Dose (Type: EXPERIMENTAL): Following run-in period with TEZ 100 mg qd/IVA 150 mg q12h for 4 weeks, participants received VX-121 20 mg qd/TEZ 100 mg qd/VX-561 150 mg qd TC for 4 weeks in the treatment period and TEZ 100 mg qd/IVA 150 mg q12h for 4 weeks in the washout period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial to Assess the Effectiveness of Applying Dry Local Heat and/ or High Tourniquet Pressure for Venipuncture.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Signed the informed consent form for bioequivalence study~* Signed the informed consent form for this clinical trial~* Fluid intake of participants was limited to a volume equal to or less than 500 ml~* Participants fasted 6-8 hours before venous cannulation~* Body mass index (BMI) between 18.5-29.9~* Vein perception by Venous International Assessment (VIA) scale between 5 to 2 grade.~Exclusion Criteria:~* Grade one in VIA scale~* Smokers~* BMI lower than 18.5 or equivalent or higher than 30~* Subjects who had any disease,~* Blood test, urinalysis, physical examination or electrocardiogram showing disorders with clinical relevance~* Subjects receiving treatment for anything apart from contraceptives.~* Gluten, lactose intolerance, vegetarian or vegan subjects for bioequivalence subjects.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Current clinical practice-Dry heat (Type: ACTIVE_COMPARATOR): The standardized and approved Clinical and Laboratory Standards Institute (CLSI) GP41-A6 venipuncture guide has been established for clinical current practice so far. According to vein cannulation procedure CLSI GP41-A6, an elastic compressor will be applied (Synthetic rubber-latex compressor tape, UNIDIX®, Madrid, Spain) provided by the hospital.~1 period (current clinical practice) and 2 period (dry heat) or 1 period (dry heat) and 2 period (current clinical practice).
- Current clinical practice- Hihg pressure (Type: ACTIVE_COMPARATOR): The standardized and approved CLSI GP41-A6 venipuncture guide has been established for clinical current practice so far. According to vein cannulation procedure CLSI GP41-A6, an elastic compressor will be applied (Synthetic rubber-latex compressor tape, UNIDIX®, Madrid, Spain) provided by the hospital.~1 period (current clinical practice) and 2 period (high pressure) or 1 period (high pressure) and 2 period (current clinical practice).
- Current clinical practice-Combination (Type: ACTIVE_COMPARATOR): The standardized and approved CLSI GP41-A6 venipuncture guide has been established for clinical current practice so far. According to vein cannulation procedure CLSI GP41-A6, an elastic compressor will be applied (Synthetic rubber-latex compressor tape, UNIDIX®, Madrid, Spain) provided by the hospital.~1 period (current clinical practice) and 2 period (combination of dry heat and high pressure) or 1 period (combination of dry heat and high pressure) and 2 period (current clinical practice).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: International Normalized Ratio (INR) Normalization in Coumadin Associated Intracerebral Haemorrhage

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Spontaneous ICH (intraparenchymal), subdural hematoma (SDH) diagnosed by CT scanning ≤ 12 hours after onset of symptoms. In case of unknown time of symptom onset: time between last seen in healthy condition and first CCT ≤ 12 hours.~* Therapy receiving vitamin K antagonists (VKA)~* International Normalized Ratio (INR) ≥ 2~* Signed informed consent form, or signed informed consent by a legal representative, judicial consent in cases where no legal representative is available in time, or consent of an independent physician familiar with the indication in cases where the first three possibilities can not be realized.~Exclusion Criteria:~* Patients with ICH not related to vitamin-K antagonist therapy or~* Patients with secondary ICH related to infarction, hemophilia or other coagulopathy, tumor, hemorrhagic infarction, cerebrovenous thrombosis, aneurysm, arteriovenous malformations (AVM) or severe trauma~* Deep Coma (GCS ≤ 5) at the time of admission or before intubation if intubated outside the hospital~* Known previous disability (mRS \> 2 before stroke occurred)~* Acute myocardial ischemia, acute septicemia, acute crush injury, any history of acute hemorrhagic disseminated intravascular coagulation, acute thrombotic stroke~* Known history of intermittent claudication~* Known recent thrombotic event \< 30 days~* Acute or known congestive heart failure (NYHA III, IV)~* Pulmonary edema~* Known liver failure (child-pugh-score C)~* Known alcohol or other drug abuse~* Known active malignant disease~* Known thrombocytopenia (platelets \<50,000/µL), hemorrhagic diathesis (primary defects of coagulation, fibrinolysis, platelets)~* History of hypersensitivity to the investigational products or to any drug with similar chemical structure or to any excipient present in the pharmaceutical form of the investigational product~* Known allergy to heparin or history of heparin induced thrombocytopenia.~* Pregnancy and lactation~* Concomitant use of antithrombotic (with PTT \> 1.5 of normal PTT), thrombolytic treatment.~* Use of aspirin, clopidogrel or dipyridamole or combinations thereof (e.g. Aggrenox®) is not an exclusion criterion. These drugs should be discontinued and not restarted earlier than 24 hours after normalization of INR if indicated.~* Previous participation in this trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Prothrombin complex concentrate (PCC) (Type: EXPERIMENTAL): intravenously, 30 IU/kg
- Fresh frozen plasma (FFP) (Type: EXPERIMENTAL): intravenously, 20ml/kg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Influence of Progesterone Administration on Drug-Induced QT Interval Lengthening

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female~* Age 21-40 years~* Premenopausal~Exclusion Criteria:~Serum potassium ,\< 3.6 meq/l~* Serum magnesium \< 1.8 mg/dl~* Serum hemoglobin \< 9.0 mg/dl~* Serum hematocrit \< 26%~* Hypertension~* Coronary artery disease~* Heart failure~* Liver disease~* Kidney disease~* Serum creatinine \> 1.5 mg/dl~* Taking hormone contraceptives~* Baseline Bazett's correct QTc interval \> 450 ms~* Family history of long-QT syndrome, arrhythmias, sudden cardiac death~* Concomitant use of any QT prolonging drug~* Pregnancy~* weight \< 45 kg~* Unwillingness to use non-hormonal forms of birth control during the study period

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Progesterone (Type: EXPERIMENTAL): Subjects will receive treatment with oral progesterone 400 mg once daily (two x 200 mg capsules) every evening for 7 days
- Placebo (Type: PLACEBO_COMPARATOR): Subjects will receive oral placebo, two capsules once daily every evening for 7 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Telephone Cognitive Behavior Therapy for OEF Veterans With Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~To be eligible to participate in this study, potential subjects must have:~* access to a telephone~* documented pain for at least the past year~* a pain disorder involving muscle strain and inflammation, trauma to nerves, or central nervous system dysfunction~* pain condition must be stable~* must have no clear indication for specific medical/surgical intervention.~Exclusion Criteria:~Patients were excluded who were:~* acutely psychotic~* cognitively impaired~* showed significant suicidal risk (history of multiple suicide attempts or actively suicidal)~* currently abusing alcohol or other drugs, including prescribed opioid pain medications~* patients were also excluded who had an unstable medical condition and clear indication for specific medical/surgical intervention in the near future.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 - Telephone CBT (Type: EXPERIMENTAL): telephone cognitive behavior therapy for pain management
- Arm 2 - telephone education (Type: ACTIVE_COMPARATOR): telephone pain education

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Promote Weight Loss in Primary Care Practices

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Obese~* Metabolic syndrome~* Read and write English~* Planning to stay in treatment with their PCP for the next 3 years~* On stable doses of medications for chronic diseases such as hypothyroidism for 3 years~Exclusion Criteria:~* Unstable health~* Diabetes mellitus~* Severe medical comorbidities that might interfere with their ability to participate in intervention such as severe psychiatric disease or significant heart disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Individual Telephone Intervention (Type: EXPERIMENTAL): Individually administered weight loss intervention, based on the Diabetes Prevention Program, delivered by telephone in primary care practices.
- Group Telephone Intervention (Type: ACTIVE_COMPARATOR): Group education conference calls to deliver the weight loss intervention, based upon the Diabetes Prevention Program, in primary care practices.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes (diagnosed clinically) for at least 6 months prior to the screening visit (Visit 1)~* Current treatment with once daily insulin detemir, insulin glargine or human isophane insulin, NPH for at least 3 months prior to the screening visit (Visit 1)~* Current treatment with a) metformin with unchanged dosing for at least 3 months prior to screening (visit 1). The metformin dose must be at least 1000 mg or b) metformin in combination with sulfonylurea (SU) or glinide or Dipeptidyl peptidase-IV inhibitors and/or alpha-glucosidase inhibitors (AGI) with unchanged dosing for at least 3 months prior to screening (visit 1). The metformin dose must be at least 1000 mg~* HbA1c by central laboratory a) 7.5-9.5% (58 - 80 mmol/mol) (both inclusive) in the metformin group at the screening visit (Visit 1) or b) 7.5-9.0% (58 - 75 mmol/mol) (both inclusive) in the metformin + other oral antidiabetic drug (OAD) (sulphonylurea (SU), glinide, dipeptidyl peptidase-IV (DDP-IV) inhibitors, alpha-glucosidase inhibitors (AGI) combination group at the screening visit (Visit 1)~* Body mass index (BMI) equal or less than 40.0 kg/m\^2~Exclusion Criteria:~* Any use of bolus insulin, except short-term use due to intermittent illness (no longer than 14 days of consecutive treatment) and not within 3 months prior to the screening visit (Visit 1)~* Use of Glucagon-like peptide-1 (GLP-1) agonists and/or Thiazolidinediones (TZD) within the last 3 months prior to screening (visit 1)~* Recurrent severe hypoglycaemia (more than one severe hypoglycaemic event during the last 12 months) or hypoglycaemic unawareness as judged by the Investigator, or hospitalisation for diabetic ketoacidosis during the previous 6 months prior to screening (Visit 1)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FIAsp and basal insulin + metformin (Type: EXPERIMENTAL): Subjects will receive FIAsp combined with their pre-trial basal insulin (insulin human, insulin detemir or insulin glargine) treatment in combination with their pre-trial metformin.
- Basal insulin + metformin (Type: ACTIVE_COMPARATOR): Subjects will continue their pre-trial basal insulin (insulin human, insulin detemir or insulin glargine) treatment in combination with their pre-trial metformin.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Avastin (Bevacizumab) + Xeloda (Capecitabine)as Maintenance Therapy in Patients With HER2-Negative Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, \>=18 years of age;~* HER2-negative metastatic breast cancer~* candidates for taxane-based chemotherapy;~* ECOG performance status of 0 or 1.~Exclusion Criteria:~* previous chemotherapy for metastatic breast cancer;~* prior adjuvant/neo-adjuvant chemotherapy within 6 months prior to study;~* prior radiotherapy for treatment of metastatic disease;~* chronic daily treatment with aspirin (325 mg/day) or clopidogrel(\>75mg/day).

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Avastin (bevacizumab) (Type: ACTIVE_COMPARATOR): None
- Avastin (bevacizumab) + Xeloda (capecitabine) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dosage Reduction and Acute Glycemic Complications in People With Type 2 Diabetes Who Fast During Ramadan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Prospective participant is a returning patient with type 2 diabetes;~* Prospective participant expressed an intention to fast during Ramadan;~* Prospective participant has been compliant with one of four glucose-lowering multidrug regimens for at least the past three months.~Exclusion Criteria:~* Prospective participant is a pregnant, postpartum, breastfeeding, or eumenorrheic woman;~* Prospective participant has experienced diabetic ketoacidosis or hyperosmolar hyperglycemic state within three months;~* Prospective participant has received niacin or corticosteroids within one month; and,~* Prospective participant has any history of recurrent hypoglycemia, hypoglycemia unawareness, chronic renal insufficiency (stages IV or V), liver cirrhosis, uncontrolled epilepsy, depressive disorder, bipolar disorder, psychotic disorder, or cognitive dysfunction.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Low-dosage therapy (Type: EXPERIMENTAL): None
- Regular-dosage therapy (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Determining Optimal Continuation Treatment Duration for Depressed Children and Adolescents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Currently being treated on an outpatient basis~* Currently attending school~* Diagnosis of non-psychotic major depressive disorder (MDD)~* Duration of illness is at least 4 weeks~* In good general medical health~* Normal intelligence~Exclusion Criteria:~* Lifetime history of any psychotic disorder, including psychotic depression~* Diagnosis of bipolar I or II disorder~* History of alcohol or substance abuse or dependence within 6 months of study entry~* Lifetime history of anorexia nervosa or bulimia~* Pregnant or breastfeeding~* Does not agree to use an effective form of contraception (i.e., IUD, birth control pills, or barrier devices)~* Any chronic medical illness requiring regular medication~* Currently taking medication with psychotropic effects (i.e., anticonvulsants, steroids, etc.), other than stable stimulant treatment~* A first degree relative has bipolar I disorder~* Previous adequate treatment with fluoxetine was ineffective (defined as at least 20 mg/day for 4 weeks)

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Early Treatment With Deferiprone in Infants and Young Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female aged ≥ 6 months to \< 10 years~2. Confirmed diagnosis of beta-thalassemia, as determined by high performance liquid chromatography (HPLC) or DNA testing~3. Started on a red blood cell (RBC) transfusion regimen, with a minimum of 2 transfusions already completed~4. Screening level of serum ferritin (SF) greater than \>200 μg/L but not more than 600 μg/L. Since SF level may be impacted by the presence of infection, it must additionally be verified that the child has had no signs of infection in the previous 7 days, including the day of screening, and that the level of C-reactive protein (CRP) is no greater than 20% higher than the normal range for the patient's age. If there are signs of infection and/or the CRP level is above this threshold, the SF level must be checked again a minimum of one week later.~Exclusion Criteria:~1. Prior use of iron chelation~2. Diagnosis of hepatitis B or C, or HIV infection~3. Evidence of abnormal liver or kidney function at screening: serum alanine transaminase (ALT) level \> 5 times upper limit of normal or creatinine levels \>2 times upper limit of normal~4. Disorders associated with neutropenia (absolute neutrophil count \< 1.5 x 10\^9/L) prior to the initiation of study medication~5. A serious, unstable illness, as judged by the investigator, during the previous 3 months before screening/baseline visit including but not limited to hepatic, renal, gastro-enterologic, respiratory, cardiovascular, endocrinologic, neurologic or immunologic disease.~6. Presence of any medical condition which in the opinion of the investigator would cause participation in the study to be unwise.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 9 Years
- Healthy Volunteers: f

Study Arms:
- Deferiprone (Type: EXPERIMENTAL): Subjects in this group will receive deferiprone oral solution at a dosage up to 75 milligrams per kilogram of body weight (mg/kg) per day, divided into 3 equal doses
- Placebo (Type: PLACEBO_COMPARATOR): Subjects in this group will receive placebo solution at a volume equal to what they would receive if they were in the active arm, divided into 3 equal doses

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete